FDA recommends lower doses of anemia drugs

Jun 24, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Food and Drug Administration officials say doctors should use lower doses of anemia drugs when treating patients with failing kidneys due to the increased risk of stroke, blood clots and death.

The new warnings announced Friday are the latest to hit the widely used medications since 2007, when the first linked them to fatal side effects.

The medicines - Procrit, Aranesp and Epogen - are multibillion-dollar sellers because of their ability to boost oxygen-carrying , reducing the need for painful blood transfusions. But a study published in 2009 suggested they could double the risk of stroke. Doctors had previously assumed that higher doses would help prevent , stroke and other .

All three of the drugs are manufactured by biotech giant Amgen Inc., while Procrit is sold by Johnson & Johnson

Doctors must adjust each patient's dosing to maintain healthy levels of hemoglobin, a component of blood that carries oxygen and helps keep patients active. Anemia causes weakness and shortness of breath and is a side effect of chemotherapy and kidney failure. FDA's announcement specifically deals with patients who are not yet on dialysis, the treatment for late-stage kidney failure.

The old labeling for the drugs recommended keeping patients' hemoglobin levels between 10 grams and 12 grams per deciliter.

The new label does away with that specific target range, stating only that doctors should begin using the drugs if patients' hemoglobins fall below 10 grams per liter.

"The goal is to individualize therapy and use the lowest dose possible to reduce the need for red blood cell transfusions," said Dr. Robert Kane, of FDA's division of hematology products. Kane said there is no way to make an all-purpose dosing recommendation that covers all patients.

More than 20 million people in the U.S. have chronic kidney disease, according to the Centers for Disease Control and Prevention.

Deutsche Bank analyst Robyn Karnauskas said most investors have already priced the labeling changes into sales expectations. Wall Street analysts generally expect sales of the drugs to decline by 8 percent in 2012, Karnauskas said in an email.

Amgen, based in Thousand Oaks Calif., licenses Procrit to Johnson & Johnson's Centocor Ortho Biotech division, under a long-standing agreement between the companies.

Explore further: FDA OKs Cubist antibiotic for serious infections

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

FDA panel backs anemia drugs for kidney disease

Oct 18, 2010

(AP) -- Federal health advisers say patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

39 minutes ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.